Innovation overload: JNJ talks new science born from old world business strategy
This article was originally published in Scrip
Proximity is the key for future developments in science, Johnson and Johnson's UK innovation head Patrick Verheyen has told Scrip in a discussion surrounding the big pharma's 2014 goals for its globally scattered innovation centers, since their launch nearly a year ago.
You may also be interested in...
The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.
Coaching and mentoring are important tools for the leaders of today to be able to foster the next generation of talent in the biopharma sector. While the routes into industry have not changed dramatically – most leaders hold a master’s degree and/or PhD – the expectations of rising leaders have altered and the industry itself has become more collaborative.
Angeli Möller, recently spotlighted by In Vivo as a 2020 Rising Leader, has quickly moved up the ranks at Bayer and is now spearheading one of its key initiatives to bring artificial intelligence and machine learning technologies into the pharma business.